Barricade Therapeutics, Granted CPRIT Grant for Colorectal Cancer Treatment
Barricade Therapeutics, a biopharma company focused on colorectal cancer, has been awarded a grant from the Cancer Prevention and Research Institute of Texas (CPRIT) to advance the Phase 1 clinical development of BT-1501 for APCmut advanced colorectal cancer patients. Barricade plans to begin the expansion of the drug development team and executives to advance the clinical development of BT-1501 as well as other pipeline drugs for cancer. 
Barricade Therapeutics, Granted CPRIT Grant for Colorectal Cancer Treatment